Worldwide unique biofeedback system for non-invasive vertigo therapy and fall prevention
Vertigo (dizziness) is the second most common symptom in medicine, causing 30% of all people worldwide to be treated at least once in their lifetime. It is caused by a disturbance of the balance organ in our inner ear and has a significant impact on our everyday life, making many activities very hard or even impossible. However, through effective balance training, the human brain is capable to compensate for the wrong sensory information and can ultimately overcome vertigo.
Unfortunately, current treatment options show severe shortcomings regarding costs, availability, and effectiveness of training. To overcome this problem, GED has developed EQUIVert. EQUIVert is the personal balance trainer for the home and professional use. It is a headphone with integrated position sensor and gesture control. It provides real-time acoustic biofeedback through sound to give the user conscious access to the otherwise unconscious combination of balance and depth sensitivity.
EQUIVert is a complete system and ready to use. All exercises and training programmes are already preinstalled in the audio guide and it dynamically adapts the exercises to training progress and individual form. The major benefits for the users are the low purchase price, the effectiveness of the training, the ease of use, and the possibility to train anytime and anywhere.
With over 100 million potential patients in Europe and the US, of which most are not or not properly treated right now, EQUIVert has a huge market creating potential. GED is planning a parallel market introduction, addressing private patients with an individual training device and healthcare physicians with a diagnosis support device. Following the already ongoing registration as medical device, EQUIVert will initially be introduced into the Central European market, shortly followed by an expansion across Europe and the US. A total of 22 new employees and an accumulated turnover of EUR 16 million is foreseen until the end of 2024.